A7RC peptide modified paclitaxel liposomes dually target breast cancer.

A7R peptide (ATWLPPR), a ligand of the NRP-1 receptor, regulates the intracellular signal transduction related to tumor vascularization and tumor growth. Here, we designed A7R-cysteine peptide (A7RC) surface modified paclitaxel liposomes (A7RC-LIPs) to achieve targeting delivery and inhibition of tumor growth and angiogenesis simultaneously. The cytotoxicity, inhibiting angiogenesis, and internalization of various liposomes by cells were assessed in vitro to confirm the influence of the peptide modification. The accumulations of A7RC-LIPs in various xenografts in mice were tracked to further identify the function of the peptide on the liposomes' surface. The results confirmed that A7RC peptides could enhance the uptake of vesicles by MDA-MB-231 cells, leading to stronger cytotoxicity in vitro and higher accumulation of vesicles in MDA-MB-231 xenografts in vivo. In addition, A7RC peptides enhanced the inhibitory effects of LIPs on the HUVEC tubular formation on Matrigel. The A7RC-LIPs may be promising drug carriers for anticancer therapy.

[1]  Vicente Micol,et al.  Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells , 2013, Breast Cancer Research and Treatment.

[2]  D. Leong,et al.  The reduction of anti-cancer drug antagonism by the spatial protection of drugs with PLA-TPGS nanoparticles. , 2014, Biomaterials.

[3]  J. Benoit,et al.  Brain targeting using novel lipid nanovectors. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Jaroslav Turánek,et al.  Liposomal paclitaxel formulations. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[5]  B. Leyland-Jones,et al.  Hypersensitivity reactions from taxol. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Stephen S. Taylor,et al.  How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.

[7]  M. Crépin,et al.  Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. , 2006, Life sciences.

[8]  Judy Mak,et al.  Neuropilin‐1 expression in cancer and development , 2012, The Journal of pathology.

[9]  C. M. Paleos,et al.  Mixed Vesicles of Didodecyldimethylammonium Bromide with Recognizable Moieties at the Interface , 1996 .

[10]  Lin Mei,et al.  Paclitaxel drug delivery systems , 2013, Expert opinion on drug delivery.

[11]  M. Tessier-Lavigne,et al.  Neuropilins in Tumor Biology , 2009, Clinical Cancer Research.

[12]  M. Reed,et al.  Neuropilins in physiological and pathological angiogenesis , 2007, The Journal of pathology.

[13]  Tianfu Wang,et al.  The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. , 2014, Biomaterials.

[14]  Haisheng Peng,et al.  Liposomes modified with p-aminophenyl-α-D-mannopyranoside: a promising delivery system in targeting the brain. , 2013, Therapeutic delivery.

[15]  Ming-hui Li,et al.  HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia–reperfusion injury in rats , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

[16]  D. Leong,et al.  Anti-migratory and increased cytotoxic effects of novel dual drug-loaded complex hybrid micelles in triple negative breast cancer cells , 2015, Nano Research.

[17]  Yan Zhang,et al.  The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. , 2011, Biomaterials.

[18]  M. I. Setyawati,et al.  In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancer. , 2015, Biomaterials.

[19]  J. Choi,et al.  Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. , 2014, Journal of nanoscience and nanotechnology.

[20]  Ulrich Beyer,et al.  Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.

[21]  Say Chye Joachim Loo,et al.  Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE–cadherin , 2013, Nature Communications.

[22]  H. Brem,et al.  Paclitaxel: a review of adverse toxicities and novel delivery strategies , 2007, Expert opinion on drug safety.

[23]  Zhengping Hu,et al.  Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[24]  Ming-hui Li,et al.  Liposomes modified with P-aminophenyl-α-D-mannopyranoside: a carrier for targeting cerebral functional regions in mice. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  Qun Wang,et al.  Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery , 2008, Journal of drug targeting.

[26]  Neil Genzlinger.  A. and Q , 2006 .

[27]  Wolfgang J. Parak,et al.  Back to Basics: Exploiting the Innate Physico‐chemical Characteristics of Nanomaterials for Biomedical Applications , 2014 .

[28]  Daming Liu,et al.  Heart-targeted nanoscale drug delivery systems. , 2014, Journal of biomedical nanotechnology.

[29]  Weipeng Cao,et al.  Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. , 2012, Biomaterials.

[30]  J. Beijnen,et al.  Liposomal drug formulations in the treatment of rheumatoid arthritis. , 2011, Molecular pharmaceutics.

[31]  W. Marsden.  I and J , 2012 .

[32]  Hongbing Deng,et al.  Functional nanoparticles in targeting glioma diagnosis and therapies. , 2014, Journal of nanoscience and nanotechnology.

[33]  Erkki Ruoslahti,et al.  Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.

[34]  Y. Hasegawa,et al.  Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer , 2011, Cancer Chemotherapy and Pharmacology.

[35]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[36]  Qun Wang,et al.  The role of glucose transporters in the distribution of p-aminophenyl-α-d-mannopyranoside modified liposomes within mice brain. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Lena Claesson-Welsh,et al.  Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. , 2011, Molecular aspects of medicine.

[38]  S. Balasubramanian,et al.  Preparation and characterization of taxane-containing liposomes. , 2005, Methods in enzymology.

[39]  Franklin Peale,et al.  Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. , 2007, Cancer cell.

[40]  B. Corfe,et al.  Neuropilins: expression and roles in the epithelium , 2012, International journal of experimental pathology.

[41]  Oku.  Anticancer therapy using glucuronate modified long-circulating liposomes. , 1999, Advanced drug delivery reviews.

[42]  D. Leong,et al.  Probing the relevance of 3D cancer models in nanomedicine research. , 2014, Advanced drug delivery reviews.

[43]  Alex L Kolodkin,et al.  Neuropilin Is a Semaphorin III Receptor , 1997, Cell.

[44]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[45]  Zhe-Sheng Chen,et al.  Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo , 2006, Cancer biology & therapy.

[46]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[47]  C. Demangel,et al.  Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis , 2000, The EMBO journal.

[48]  N. Charnaux,et al.  Lipopeptide-based liposomes for DNA delivery into cells expressing neuropilin-1 , 2006, Journal of drug targeting.

[49]  Y. Glinka,et al.  Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity , 2012, Oncotarget.

[50]  R. Stephenson.  A and V , 1962, The British journal of ophthalmology.

[51]  Hulun Li,et al.  Voriconazole into PLGA nanoparticles: improving agglomeration and antifungal efficacy. , 2008, International journal of pharmaceutics.

[52]  A. Dash,et al.  Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges. , 2009, Critical reviews in therapeutic drug carrier systems.

[53]  Yitao Wang,et al.  Advances in self-assembled chitosan nanomaterials for drug delivery. , 2014, Biotechnology advances.

[54]  Yun-Fei Xia,et al.  Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. , 2006, Cancer research.

[55]  M. Klagsbrun,et al.  Targeting endothelial and tumor cells with semaphorins , 2007, Cancer and Metastasis Reviews.

[56]  A. Safavy.  Recent developments in taxane drug delivery. , 2008, Current drug delivery.

[57]  Tianfu Wang,et al.  Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo. , 2014, Journal of materials chemistry. B.

[58]  Balaji Narasimhan,et al.  Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[59]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[60]  Feng Tian,et al.  NRP-1 expression in bladder cancer and its implications for tumor progression , 2014, Tumor Biology.

[61]  Ming-hui Li,et al.  The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers , 2012, Journal of liposome research.

[62]  A. Eichmann,et al.  Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos , 2008, Development.

[63]  W. Zhou,et al.  Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes , 2010, Nanotechnology.